We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Wyeth Extends and Expands Its Licensing of Ingenuity Pathways Analysis
News

Wyeth Extends and Expands Its Licensing of Ingenuity Pathways Analysis

Wyeth Extends and Expands Its Licensing of Ingenuity Pathways Analysis
News

Wyeth Extends and Expands Its Licensing of Ingenuity Pathways Analysis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Wyeth Extends and Expands Its Licensing of Ingenuity Pathways Analysis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ingenuity has announced that Wyeth Pharmaceuticals, Inc. has extended and expanded it’s licensing of the Ingenuity Pathways Analysis software and will be deploying it broadly across its discovery and development organizations worldwide.

Ingenuity Pathways Analysis (IPA) 3.0, released last month, designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.

With Ingenuity Pathways Analysis 3.0, scientists can integrate their own biological discoveries into Ingenuity networks, enabling computation and functional analysis.

IPA 3.0 allows scientists to create customized pathways for particular targets, biomarkers, disease areas, and processes, leveraging Ingenuity's broad knowledge base of biological relationships between genes and proteins, cells, tissues, and diseases.

“Wyeth continues to embrace pathways analysis software as a critical element to successful therapeutic research and development,” stated Peter DiLaura, Vice President, Sales and Customer Support.

“Ingenuity is pleased that Wyeth is both renewing and expanding its use of Ingenuity technology, and Ingenuity will continue its commitment to provide the highest quality pathways solutions available today.”

Ingenuity Pathways Analysis is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available to qualified scientists. 

Advertisement